4168.TWO GlycoNex
- Market cap
- TWD 2.24B
- P/E
- -
- P/B
- 2.68x
- ROE
- -30.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4168.TWO undervalued?
Graham numberThe Graham number of GlycoNex cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GlycoNex fundamental analysis
No fundamental analysis for GlycoNex yet.
GlycoNex stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company's pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases. It also develops GNX102, a humanized monoclonal antibody, which is in Phase 1 clinical trials for the treatment of various …
Full company profileGlycoNex financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GlycoNex annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 634K | 926K | 734K | 451K | 5.48M | 30.1M | 2.54M | 14.7M | 37.9M | 27.9M |
| Gross Profit | 295K | 478K | 149K | 125K | 3.46M | 14.0M | 995K | 7.32M | 23.5M | 11.5M |
| Operating Income | -161M | -322M | -270M | -159M | -172M | -215M | -158M | -246M | -250M | -275M |
| EBITDA | -90.1M | -261M | -192M | -112M | -132M | -175M | -127M | -190M | -192M | -210M |
| Net Income | -145M | -317M | -247M | -163M | -172M | -220M | -178M | -230M | -235M | -262M |
| EPS | -1.91 | -4.18 | -3.26 | -1.82 | -1.78 | -2.21 | -1.65 | -2.12 | -2.09 | -2.33 |
| Balance Sheet | ||||||||||
| Total Assets | 1.87B | 1.56B | 1.33B | 1.57B | 1.40B | 1.72B | 1.55B | 1.32B | 1.55B | 1.39B |
| Total Liabilities | 25.2M | 29.4M | 31.4M | 34.5M | 36.1M | 271M | 276M | 270M | 572M | 541M |
| Shareholders' Equity | 1.84B | 1.53B | 1.30B | 1.54B | 1.36B | 1.45B | 1.28B | 1.05B | 982M | 851M |
| Cash & Short-term Investments | 443M | 256M | 119M | 479M | 332M | 679M | 700M | 110M | 468M | 435M |
| Total Debt | - | - | - | 900K | 900K | 225M | 900K | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 61.4M | -180M | -180M | -146M | -141M | -168M | -184M | -222M | -166M | -242M |
| Capital Expenditure | 236M | 3.22M | 1.50M | 1.87M | 6.84M | 8.69M | 23.4M | 35.3M | 6.58M | 5.36M |
| Free Cash Flow | -193M | -184M | -181M | -147M | -148M | -176M | -207M | -257M | -173M | -248M |
| Ratios | ||||||||||
| ROE | -7.9% | -20.7% | -19.0% | -10.6% | -12.7% | -15.2% | -14.0% | -22.0% | -23.9% | -30.8% |
| ROA | -7.7% | -20.3% | -18.6% | -10.3% | -12.4% | -12.8% | -11.5% | -17.4% | -15.1% | -18.8% |
| Net Profit Margin | -22,805.7% | -34,227.1% | -33,682.2% | -36,082.3% | -3,150.6% | -730.7% | -7,016.6% | -1,562.5% | -621.3% | -937.6% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.16x | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GlycoNex dividends
GlycoNex has not paid dividends in the last 9 fiscal years.
Last stock split: 1100:1000 on Aug 12, 2014.
Who owns GlycoNex
- Insiders 20.11%
- Institutions 0.60%
- Public & others 79.29%
- Shares outstanding 113M
- Free float 91.4M
GlycoNex company profile
- Company name
- GlycoNex
- Ticker
- 4168.TWO
- ISIN
- TW0004168000
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 97, Xintai 5th Road, New Taipei City, Taiwan, 22175
- Phone
- 886 2 2697 4168
- Website
- glyconex.com.tw
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company's pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases. It also develops GNX102, a humanized monoclonal antibody, which is in Phase 1 clinical trials for the treatment of various solid tumor types, such as colorectal, gastric, lung, breast, and pancreatic cancers; GNX1021, an antibody"drug conjugate that has completed the preclinical stage for oncology indications; GNX201-ADC, an antibody drug in the preclinical stage for the treatment of solid tumors; and GNX203, a glycan-directed antibody drug currently in the lead optimization stage for the treatment of solid tumors, including pancreatic, colorectal, and gynecologic cancers. In addition, the company offers technical consulting services for antibody manufacturing; and general investment services. It has a collaboration with Mitsubishi Gas on the development of denosubmab biosimilar SPD8. GlycoNex Incorporation was incorporated in 2001 and is based in New Taipei City, Taiwan.
GlycoNex management
10- Dr. Tong-Hsuan ChangFounder & Chairman
- Dr. Mei-Chun Yang Ph.D.President, CEO, General Manager & Director
- Ms. Ti-Fen WuCFO, Financial & Accounting Manager and Accounting Supervisor
- Mr. Yaohua LuVice President of Administration
- Tzu-Lin YangHead of Process Development
- Yu-Ting LinHead of Clinical Development
- Wen-Han Lee Ph.D.Head of Strategy & Business Development
- Chieh-Hsin ChenHead of Analytical Development
- Yen-Ying Chen Ph.D.Head of New Drug Development
- Chun-Fu LinHead of Manufacturing